Conference
Earn CE
Free Samples
Magazine
Subscribe
Videos
Solutions Lab
Macro/Op-Ed
Practice
Science & Tech
Money
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Dental Market Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by 23andMe Holding Co.
23andMe to Report FY2023 Fourth Quarter and Full Year Financial Results
May 11, 2023
From
23andMe Holding Co.
Via
GlobeNewswire
Tickers
ME
23andMe Releases New Report Revealing Likelihood of Developing Lupus
May 09, 2023
From
23andMe Holding Co.
Via
GlobeNewswire
Tickers
ME
Reza Afkhami Joins 23andMe as Chief Corporate Development Officer
May 08, 2023
From
23andMe Holding Co.
Via
GlobeNewswire
Tickers
ME
23andMe Announces Phase 1 Results from the First-in-Human Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1
April 14, 2023
From
23andMe Holding Co.
Via
GlobeNewswire
Tickers
ME
Morehouse School of Medicine, Sickle Cell Foundation of Georgia and 23andMe Launch Sickle Cell Carrier Status Awareness Program
April 11, 2023
From
23andMe Holding Co.
Via
GlobeNewswire
Tickers
ME
23andMe Aims To Raise Awareness of Lipoprotein(a), a Little-Known Genetic Risk Factor for Cardiovascular Disease
March 24, 2023
From
23andMe Holding Co.
Via
GlobeNewswire
Tickers
ME
23andMe Announces Presentation of Phase 1 Clinical Data for 23ME-00610, an Investigational Antibody Targeting CD200R1, at the American Association for Cancer Research (AACR) Annual Meeting 2023
March 14, 2023
From
23andMe Holding Co.
Via
GlobeNewswire
Tickers
ME
New 23andMe Surveys Find Most People and Doctors Agree that Genetic Testing Offers Promise for More Personalized Healthcare
March 09, 2023
From
23andMe Holding Co.
Via
GlobeNewswire
Tickers
ME
23andMe Announces First Patient Dosed for the Phase 2a Portion of its Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1 in Patients with Advanced Solid Malignancies
February 28, 2023
From
23andMe Holding Co.
Via
GlobeNewswire
Tickers
ME
23andMe to Present at Upcoming Investor Conferences
February 22, 2023
From
23andMe Holding Co.
Via
GlobeNewswire
Tickers
ME
23andMe Reports FY2023 Third Quarter Financial Results
February 08, 2023
From
23andMe Holding Co.
Via
GlobeNewswire
Tickers
ME
23andMe to Report FY2023 Third Quarter Financial Results
January 26, 2023
From
23andMe Holding Co.
Via
GlobeNewswire
Tickers
ME
23andMe Survey Shows Majority of People Less Stressed About Their Health During This Holiday Season
December 01, 2022
From
23andMe Holding Co.
Via
GlobeNewswire
Tickers
ME
23andMe Reports FY2023 Second Quarter Financial Results
November 07, 2022
From
23andMe Holding Co.
Via
GlobeNewswire
Tickers
ME
23andMe Trials-in-Progress Poster Details Expansion Cohorts for 23ME-00610, an Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer’s (SITC) 2022 Annual Meeting
November 07, 2022
From
23andMe Holding Co.
Via
GlobeNewswire
Tickers
ME
23andMe Granted New FDA Clearance to Provide Interpretive Drug Information for a Commonly Prescribed Cholesterol Medication
October 27, 2022
From
23andMe Holding Co.
Via
GlobeNewswire
Tickers
ME
23andMe to Report FY2023 Second Quarter Financial Results
October 24, 2022
From
23andMe Holding Co.
Via
GlobeNewswire
Tickers
ME
23andMe to Present at Upcoming Investor Conferences
October 12, 2022
From
23andMe Holding Co.
Via
GlobeNewswire
Tickers
ME
23andMe Announces Trials-in-Progress Poster Presentation on 23ME-00610, An Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer’s (SITC) 2022 Annual Meeting
October 05, 2022
From
23andMe Holding Co.
Via
GlobeNewswire
Tickers
ME
23andMe to Report FY2023 First Quarter Financial Results
July 25, 2022
From
23andMe Holding Co.
Via
GlobeNewswire
Tickers
ME
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.